格隆汇7月29日｜药明康德(603259)：将回购股份价格上限由不超过90.72元/股(含)调整为不超过人民币 114.15元/股，回购方案其他内容不变。 (责任编辑：宋政 HN002) 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com ...

药明康德H股7月以来累计上涨逾42%，年内涨幅超103%，表现更胜A股。 股价大涨背后是公司坚实的业绩表现——药明康德7月28日晚间发布的2025年半年报显示，上半年公司 营收达208亿元，同比增长20.64%；净利润达85.6亿元，同比增长101.92%，创上市以来最佳半年表现； 扣非净利55.82亿元，同比增长26.47%；毛利率提升至44.45%，亦创上市以来半年报数据最高纪录。 靓丽的半年报发布后，多家外资投行就药明康德发布研报上调公司目标价。 转自：新华财经 新华财经上海7月29日电（林郑宏）7月29日，A股三大股指延续涨势，沪指收盘站上3600点整数关口， 收盘点位创年内新高；深成指涨0.64%，创业板指大涨1.86%，自去年11月13日后收盘点位首次突破 2400点整数关口。 医药股成为推动创业板指上涨的主要动力，CXO、减肥药、创新药等概念板块领涨两市，其中CXO板 块涨幅居首。成交额超过10亿元的8只行业主题类ETF中，易方达沪深300医药ETF（512010）上涨 2.68%，成交13.63亿元，位列第4；华宝中证医疗ETF（512170）上涨2.45%，成交11.52亿元，位列第 7。 ...

证券代码：603259 证券简称：药明康德 公告编号：临 2025-052 无锡药明康德新药开发股份有限公司 1 年 6 月 25 日披露的《关于 2025 年第一次以集中竞价交易方式回购 A 股股份的 回购报告书》（公告编号：临 2025-042）。 二、回购股份的进展情况 截至 2025 年 7 月 28 日，公司在本次回购方案下累计通过集中竞价交易方 式回购 A 股股份 6,514,425 股，占公司总股本的 0.23%，回购最高价格为人民币 90.70 元/股，回购最低价格人民币 65.53 元/股，回购价格均价人民币 76.34 元/ 股，使用资金总额人民币 497,297,934.64 元（不含交易费用）。 关于调整回购股份价格上限的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 无锡药明康德新药开发股份有限公司（以下简称"公司"）于 2025 年 7 月 29 日召开第三届董事会第二十三次会议，审议通过了《关于调整回购股份价 格上限的议案》，公司拟将 2025 年第一次以集中竞价交易方式回购 ...

Market Overview - The Hang Seng Index closed at 25,524.45, down by 0.15%, while the Hang Seng China Enterprises Index fell by 0.34% to 9,145.92. The Hang Seng Tech Index decreased by 0.35% to 5,644.38, with intraday declines reaching 1.2% for the first two indices and a significant drop of 2% for the tech index [1] - Despite the index adjustments, southbound capital saw a substantial net purchase of Hong Kong stocks exceeding 10 billion HKD [1] Stock Performance - Notable gainers in the biopharmaceutical sector included WuXi AppTec (up 11.25%), with other companies like CSPC Pharmaceutical and Green Leaf Pharmaceutical also showing strong performance, rising over 8% [3] - The top-performing stocks included WuXi Biologics-B (up 33.33%), Chuangsheng Group-B (up 17.06%), and Dongyao Pharmaceutical-B (up 15.06%) [2] Sector Trends - Large tech stocks showed a narrowing of losses in the afternoon, with Alibaba slightly turning positive, while Tencent, JD.com, Meituan, and Kuaishou experienced declines within 1%. Xiaomi fell by 2.6%, and Baidu dropped nearly 2% [3] - The "anti-involution" sectors, including steel and photovoltaic stocks, saw a rebound, while sectors like banking, catering, and robotics generally declined [3]

人民财讯7月29日电，药明康德（603259）7月29日晚间公告，拟将2025年第一次以集中竞价交易方式回 购A股股份的回购股份价格上限由不超过90.72元/股（含）调整为不超过114.15元/股，本次回购方案的 其他内容不变。 ...

Market Overview - The Hong Kong stock market indices showed a recovery in the afternoon, with the Hang Seng Index and the Hang Seng China Enterprises Index down by 0.15% and 0.34% respectively, while the Hang Seng Tech Index fell by 0.35% after a larger drop of 2% during the day [1][2] - Despite the index adjustments, southbound funds significantly net bought over 10 billion HKD in Hong Kong stocks [1] Sector Performance - Large tech stocks saw a narrowing of losses in the afternoon, with Alibaba slightly turning positive, while Tencent, JD.com, Meituan, and Kuaishou experienced declines within 1%. Xiaomi continued to decline by 2.6% [2] - Biopharmaceutical stocks performed strongly, particularly in the innovative drug sector, with WuXi AppTec rising over 11%, and both CSPC Pharmaceutical and Luye Pharma increasing by over 8% [2] - The "anti-involution" sectors, including steel and photovoltaic stocks, showed a notable recovery, while oil, gambling, and semiconductor stocks mostly rose [2] - The three-child policy subsidy of 3600 yuan led to a mixed performance in related stocks, with some experiencing declines [2][6] Banking Sector - The banking sector faced declines, with several banks such as Chongqing Rural Commercial Bank and China Everbright Bank dropping over 3% [4][5] - Major banks like Industrial and Commercial Bank of China, China Construction Bank, and Agricultural Bank of China also saw declines [4] Biopharmaceutical Sector - WuXi AppTec reported a strong performance with a revenue of 20.8 billion yuan for the first half of 2025, a year-on-year increase of 20.64%, and a net profit surge of 101.92% [8] - The company expects continued double-digit growth in operating revenue, adjusting its growth forecast from 10-15% to 13-17% [8] Automotive Sector - Automotive dealership stocks rose against the trend, with Guanzhong Holdings increasing over 9% and Zhongsheng Holdings up over 6% [9][10] - UBS reported that the rebound in stock prices for Zhongsheng and Yongda Automotive is attributed to expectations of improved profit margins from new car sales due to government policies [10] Steel Sector - Steel stocks experienced gains, with Maanshan Iron & Steel rising over 8% and several other companies like Ansteel and Asia Pacific Resources also seeing increases [11][12] Apple-Related Stocks - Apple-related stocks were active, with AAC Technologies rising over 3% and other companies like GoerTek and BYD Electronics also showing gains [13] Future Outlook - Haitong Securities expressed optimism about the Hong Kong stock market, particularly in the technology sector, suggesting a focus on sectors with improving conditions and low valuations [15]

（文章来源：每日经济新闻） 每经AI快讯，7月29日，药明康德公告，将回购股份价格上限由不超过90.72元/股（含）调整为不超过 114.15元/股，回购方案其他内容不变。 ...

Core Viewpoint - The company reported strong financial performance for H1 2025, driven by high demand in the TEDIS business, leading to an upward revision of its annual performance guidance [1][4]. Group 1: Financial Performance - In H1 2025, the company achieved revenue of 20.8 billion yuan, a year-on-year increase of 20.6%, with continuous operations revenue growing by 24.2% [1]. - Adjusted net profit attributable to shareholders reached 6.31 billion yuan, up 44.4% year-on-year, while the net profit attributable to shareholders was approximately 8.56 billion yuan, reflecting a 101.9% increase [1]. - For Q2 2025, the company reported revenue of 11.14 billion yuan, a 20.4% year-on-year growth, and adjusted net profit of 3.64 billion yuan, up 47.9% [1]. Group 2: Business Segments - **Chemical Business (WuXi Chemistry)**: H1 2025 revenue was 16.3 billion yuan, a 33.5% increase, with an adjusted gross margin of 49.0%, up 5.2 percentage points. The TIDES business saw revenue of 5.03 billion yuan, a significant 141.6% increase [2]. - **Testing Business (WuXi Testing)**: H1 2025 revenue was 2.69 billion yuan, a slight decline of 1.2%, with an adjusted gross margin of 25.1%, down 12.3 percentage points. Q2 2025 showed signs of recovery with a 5.5% year-on-year growth in laboratory analysis and testing services [3]. - **Biology Business (WuXi Biology)**: H1 2025 revenue was 1.25 billion yuan, a 7.1% increase, with an adjusted gross margin of 36.4%, down 0.7 percentage points. The business contributed to over 30% of new customer acquisition [4]. Group 3: Market Dynamics - The company has a strong international presence, with approximately 85% of revenue coming from overseas clients. Revenue from U.S. clients was 14.03 billion yuan, up 38.4%, while revenue from Chinese clients decreased by 5.2% to 3.15 billion yuan [5]. - The company’s order backlog for continuous operations reached 56.69 billion yuan, a 37.2% year-on-year increase, indicating robust future growth potential [4]. Group 4: Future Outlook - The company has revised its 2025 revenue growth target for continuous operations from 10-15% to 13-17%, with overall revenue targets adjusted from 41.5-43 billion yuan to 42.5-43.5 billion yuan [4]. - The company expects to maintain strong growth trends in the second half of 2025, supported by high demand in the TEDIS business [4].

Core Insights - Morgan Stanley's research report indicates that WuXi AppTec's revenue and adjusted net profit for the first half of the year increased by 21% and 44% year-on-year, exceeding the bank's expectations by 5% and 15% respectively, with the second quarter showing increases of 20% and 48% [1] - The management has raised the full-year revenue growth guidance to 13% to 17%, suggesting revenue will be between 42.5 billion to 43.5 billion yuan, reflecting confidence in the second half performance and providing a buffer against last year's high base [1] - The TIDES business is expected to be a key driver for the full-year performance, with its revenue in the first half increasing 1.42 times to 5 billion yuan, accounting for over 30% of the chemical business's total revenue and approximately 24% of the company's overall revenue; solid-phase peptide synthesis capacity is anticipated to double by 2025 [1] - Morgan Stanley has set a target price of 92 yuan for WuXi AppTec's A-shares and maintains an "Overweight" rating [1] Related Events - Major banks have issued ratings for WuXi AppTec, with Morgan Stanley stating that the company's first-half performance exceeded expectations and maintaining a target price of 92 yuan and an "Overweight" rating [2] - Bank of America has raised its target price for WuXi AppTec to 115.7 Hong Kong dollars, citing strong growth in new orders during the first half [2]

Core Viewpoint - Citigroup's research report indicates that WuXi AppTec (2359.HK) experienced a 21% year-on-year revenue growth to 20.8 billion RMB in the first half of the year, with net profit increasing by 102% to 8.6 billion RMB, aligning with previous earnings guidance [1] Financial Performance - Revenue for the first half of the year reached 20.8 billion RMB, marking a 21% increase compared to the previous year [1] - Net profit surged by 102% to 8.6 billion RMB, and when excluding one-time gains, the growth rate was 26% [1] Guidance and Projections - Management has raised the full-year revenue guidance from the previous range of 41.5 billion to 43 billion RMB to a new range of 42.5 billion to 43.5 billion RMB [1] - The expected growth for ongoing operations is now projected at 13% to 17%, up from the earlier forecast of 10% to 15% [1] - There is confidence in further improving the adjusted net profit margin [1] Analyst Ratings - Citigroup has set a target price of 95 HKD for WuXi AppTec, rating it as a "Buy" and plans to update after the earnings conference call [1] - Morgan Stanley has rated WuXi AppTec with a target price of 92 RMB and an "Overweight" rating, citing better-than-expected performance in the first half [1] - Bank of America has raised its target price for WuXi AppTec to 115.7 HKD, highlighting strong growth in new orders during the first half [1]